"Seeing her smile was the best thing ever," Rubi Rojas tells PEOPLE of the moment her daughter Lorelai put on the wig made of ...

Deuruxolitinib is the latest JAK inhibitor to enter the UK alopecia areata treatment landscape, pending a NICE decision on ...

The UK's medicines watchdog has given the green light to deuruxolitinib, also known as Leqselvi, a treatment for people with severe alopecia areata.

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

GPT-4o achieved ICC/CCC of 0.815/0.866 versus in-person SALT scoring and 0.833/0.817 versus image-based scoring, while expert ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Leqselvi (deuruxolitinib), made by Sun Pharma UK, as a treatment for severe alopecia areata in adults. Alopecia areata is a ...

Providers say early treatment matters, especially for scarring hair loss, which can become permanent.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Indian drugmaker Sun Industries’ Leqselvi ...

Summer can be harsh on the hair, and you are likely to experience hair thinning and increased shedding. The bald patches can be quite a concern, but there are ways to treat the problem. Take a look.

UK MHRA approves Sun Pharma’s deuruxolitinib to treat severe alopecia areata in adults: United Kingdom Friday, March 13, 2026, 09:00 Hrs [IST] The Medicines and Healthcare produ ...

Moby Strategic Performance and Operational Context. Management attributes the 2025 performance to the successful validation of ...